Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Guselkumab for Psoriasis
Recruiting2 awardsPhase 4
Boston, Massachusetts
This trial tests Guselkumab, a medication that reduces inflammation, on high-risk psoriasis patients to prevent them from developing Psoriatic Arthritis. The drug works by blocking IL-23, a molecule that causes inflammation. Guselkumab is approved for treating moderate-to-severe plaque psoriasis.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.